By Fineline Cube Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has received clinical approval from China’s National Medical Products Administration (NMPA) for its integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC) SKB105, which will now be evaluated in advanced solid tumors.
Development & Partnership Milestone
| Parameter | Detail |
|---|---|
| Company | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) |
| Drug Candidate | SKB105 (ITGB6-targeted ADC) |
| Original Designation | CR-001 (Crescent Biopharma) |
| Regulatory Approval | NMPA clinical study authorization |
| Indication | Advanced solid tumors |
| Licensing Agreement | December 2025 with Crescent Biopharma, Inc. (US) |
| Territory Rights | Mainland China, Hong Kong, Macau, Taiwan (exclusive) |
Global Clinical Development Program
ASCEND Phase I/II Study
The drug is already enrolled in the global Phase I/II ASCEND study:
| Study Parameter | Detail |
|---|---|
| Study Name | ASCEND |
| Phase | I/II |
| Indication | Locally advanced or metastatic solid tumors |
| Global Approval | January 2026 |
| Planned Enrollment | 290 patients |
| Geographic Scope | Multi-center, international |
Chinese Clinical Integration
The newly granted NMPA approval enables:
- Chinese patient enrollment in the global ASCEND study
- Local clinical data generation for potential China-specific regulatory submissions
- Expanded access to Chinese patient populations with advanced solid tumors
Target Rationale & Therapeutic Innovation
Integrin Beta-6 (ITGB6) Biology
- Tumor-selective expression: ITGB6 overexpressed in multiple epithelial cancers while limited in normal tissues
- Metastasis association: High ITGB6 expression correlates with aggressive disease and poor prognosis
- Therapeutic window: Target profile supports selective ADC delivery with reduced off-target toxicity
- Multiple tumor types: Expression validated across lung, pancreatic, colorectal, and other solid malignancies
ADC Platform Advantages
SKB105 leverages established ADC technology with novel target application:
- Precision targeting: Antibody component specifically binds ITGB6 on tumor cells
- Controlled payload delivery: Cytotoxic agent released intracellularly following internalization
- Bystander effect potential: May impact neighboring tumor cells in heterogeneous tumors
- Combination compatibility: Suitable for combination with immunotherapy and targeted agents
Strategic Partnership Framework
Crescent Biopharma Licensing Deal
The December 2025 agreement established comprehensive regional rights:
| Partnership Element | Detail |
|---|---|
| Licensing Partner | Crescent Biopharma, Inc. (US) |
| Asset Acquired | SKB118/CR-001 (now SKB105) |
| Exclusive Territories | Greater China (Mainland China, Hong Kong, Macau, Taiwan) |
| Rights Scope | Development, manufacturing, and commercialization |
| Global Coordination | Integration with ongoing international clinical program |
Strategic Rationale for Kelun-Biotech
- Pipeline diversification: Adds novel ADC mechanism to existing oncology portfolio
- International validation: Leverages US-developed asset with global clinical data
- Market access: Exclusive Greater China rights provide significant commercial opportunity
- Development acceleration: Builds on existing global clinical program rather than starting de novo
Market Context & Competitive Landscape
ADC Market Evolution
- Target innovation: Shift toward novel targets like ITGB6 beyond traditional HER2/TROP2
- Solid tumor focus: Growing emphasis on epithelial cancers with high unmet need
- Chinese ADC leadership: Domestic companies increasingly developing innovative ADC platforms
- Global partnerships: Cross-border licensing deals accelerating Chinese biotech globalization
Solid Tumor Treatment Gap
- Advanced disease challenge: Limited effective options for metastatic solid tumors post-standard therapy
- Target validation: ITGB6 represents emerging target with strong biological rationale
- Combination potential: ADC platform suitable for integration with existing treatment paradigms
The NMPA approval positions SKB105 as a promising addition to China’s growing ADC pipeline, combining international innovation with domestic development expertise to address significant unmet needs in advanced solid tumors.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and partnership outcomes. Actual results may differ due to risks including clinical trial outcomes, safety profile, and competitive dynamics.-Fineline Info & Tech